Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01082627
Other study ID # Nanjing Jinling Hospital
Secondary ID
Status Completed
Phase Phase 4
First received March 5, 2010
Last updated August 2, 2011
Start date June 2009
Est. completion date November 2010

Study information

Verified date February 2010
Source Nanjing PLA General Hospital
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Primary Objective:

To demonstrate whether an early fixed Somatostatin treatment improves the complete recovery rate of early postoperative simple small bowel obstruction (EPSSBO) compared with the common daily practice

Notes:

1. complete recovery= toleration of solid food+ flatus+ passage+ recovery of bowel movement.

2. common daily practice includes:

- NPO (Nil per mouth), re-dehydration, TPN (Total Parenteral Nutrition) if needed. Check & make sure stability of electrolytes daily.

- GI (Gastro-Intestinal) depression via NGT (Naso-Gastric Tube)

- Discontinue opiates, instead of NSAIDs. (Non-Steroidal Anti-Inflammatory Drugs)

- Pro-dynamic drugs or other drugs which may interfere with GI (Gastro-Intestinal) movement eg. anti-histamines, anti-cholinergic, opiates, anti-depressives are not indicated.

Secondary Objectives:

To investigate whether an early fixed Somatostatin treatment will bring much benefit to EPSSBO pts compared with the common daily practice,for this purpose,the study will investigate the endpoints below.


Description:

1. Study Design:

This is a multi-centers, open label, randomized study , and will enroll 80 EPSSBO patients, who will be assigned to two groups randomly. All the inclusive patients will be consistent with the diagnosis of EPSSBO, and the mechanic SBO or the strangulating SBO will be ruled out in advance.

The inclusive patients will be assigned to two groups as follow(ratio 3:1)

- Arm A: Somatostatin+common daily practice(60).

- Arm B: common daily practice only(20).

2. Total number of subjects:80 EPSSBO patients.

3. Schedule of visits and assessments,The following assessments will be performed.

- Pre-screening:informed consent,demographic data,EPSSBO diagnosis.

- Screening

- Daily visit:

- Weekly visit:

- End of study visit:

4. Statistical methods

- As this will be a pilot study, no formal statistical calculations were carried out and the sample size was estimated as 80 EPSSBO subjects in a 3:1 ratio of active to control subjects i.e. 60 for Stilamin+ common daily practice and 20 for common daily practice only.

- The primary endpoint of the complete recovery rate will be estimated for both treatment groups, with 95% confidence intervals. The difference in the proportions between the treatment groups will also be estimated and treatment comparisons will be performed using a chi-square test. All statistical tests will be 2-tailed with a significance level of 0.05.

- Descriptive statistics including number (N), mean, median, standard deviation, minimum and maximum, will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.

- Continuous variables will be analyzed using an analysis of variance (ANOVA) model with effect for treatment only. The data will be checked for normality. If the distributions are normal, parametric techniques will be used. If the data are not normally distributed, non parametric techniques will be used. These assumptions will also apply to the primary endpoint i.e. use of non-parametric tests if necessary. All statistical tests will be 2-tailed with a significance level of 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patient has given written informed consent before any study-related activities are carried out.

- Males and females,aged 18-70.

- Recent open abdominal surgery history.

- Having the following symptoms or signs after 5 days of index operation: abdominal distention + inability to pass flatus + inability to passage + weak or absent bowel sound.

- X-ray:paucity of bowel gas,0-1 air-fluid level.

- CT:intestinal wall edema/thickness,no mechanic obstruction

Exclusion Criteria:

- After laparoscopic surgery.

- Recent drug history of anti-histamines,anti-cholinergic,anti-depressives,post-operative usage of opiates.

- Any of below:severe abdominal pain,colic,peritoneal sign,hig-pitched bowel sound,T>38?,tachycardia,bradycardia,WBC>12000/ul,X-ray=2 air-fluid levels,CT:mechanic obstruction.

- Any of below: Abdominopelvic abscess,Anastomotic leaks, Appendicitis,Cholecystitis,Hemoperitoneum or retroperitoneal hemorrhage, Hypokalemia, Hypomagnesemia, Pancreatitis, Sepsis.Uremia.

- Severe heart failure(NYHA III and above).

- History of arrhythmia or syncope.

- ECG QTc >0.44s.

- Severe renal function insufficiency (Calculated Creatinine Clearance Rate (Ccr) <30ml/min).

- Severe Liver function insufficiency(CHILD B~C).

- Hyper or hypothyroidism intracranial GH-secreting tumor.

- Brittle DM.

- Pregnancy.

- Allergy to any ingredient of Stilamin.

- History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder.

- Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Somatostatin
250ug/h,Continuous I.V. infusion,maximal 14 days
Other:
common daily practice
common daily practice

Locations

Country Name City State
China Nanjing PLAGH Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete recovery rate of EPSSBO = (Num. of patients with complete recovery of EPSSBO per group/Total num. of patients per group) * 100 14 days No
Secondary Average recovery time 14 days No
Secondary Re-surgery rate 14 days No
Secondary Average NG (naso-gastric) aspirate volume 14 days No
Secondary Average re-dehydration volume 14 days No
Secondary Change of blood electrolytes 14 days No
Secondary Degree of symptom and sign relief 14 days No
See also
  Status Clinical Trial Phase
Completed NCT02065661 - Product Validation Study of 2 New Devices, EZ-NG (RightSpot pH Indicator) and EZ-pH (RightLevel pH Indicator) N/A
Completed NCT05517057 - Radiologic Score and Failure of Conservative Management of Adhesive Small Bowel Obstruction
Not yet recruiting NCT05864378 - POCUS for Small Bowel Obstruction in the ED: a Retrospective Study
Terminated NCT03573921 - Gastrografin for Treating Small Bowel Obstruction in Children Phase 2/Phase 3
Recruiting NCT05315765 - Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
Not yet recruiting NCT01934283 - Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation N/A
Not yet recruiting NCT04001985 - Nasogastric Tube Clamping Trial vs. Immediate Removal N/A
Enrolling by invitation NCT05878015 - A Study of Intravenous Acetaminophen for Small Bowel Obstruction Phase 4
Recruiting NCT03139149 - Comparison of Early Operative Treatment and 48 h Conservative Treatment in Small Bowel Obstruction N/A
Active, not recruiting NCT06101719 - Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
Completed NCT00389116 - Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Phase 4
Not yet recruiting NCT05843097 - SnapSBO - Small Bowel Obstruction Snapshot Audit
Completed NCT05662384 - Small Bowel Obstruction. A Prospective Multicener Study
Completed NCT04929275 - Enhanced Recovery Programs and Small Bowel Obstruction N/A
Not yet recruiting NCT06140173 - Low-osmolar Water Soluble Contrast Agent in Management of Adhesive Small Bowel Obstruction N/A
Completed NCT03461744 - Diagnostic Scoring for Small Bowel Obstruction
Completed NCT02190981 - Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Completed NCT01524081 - Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures Phase 3
Recruiting NCT06065150 - Early Surgery Versus 3 Days Non-surgical Management in Acute Small Bowel Obstruction (SURGI-BOW) N/A
Completed NCT03386136 - Therapeutic Oxygen for Gastrointestinal Atony (TOGA) Phase 1